nach oben

Journal of Inherited Metabolic Disease

Erschienen in:

01.05.2014 | Review

Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis

Effectiveness of ERT in different disease stages

verfasst von: Saskia M. Rombach, Bouwien E. Smid, Gabor E. Linthorst, Marcel G. W. Dijkgraaf, Carla E. M. Hollak

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

Current available evidence on long-term effectiveness of enzyme replacement therapy (ERT) for Fabry disease is limited. More insight is needed whether ERT effectiveness differs in patients with and without baseline end-organ damage.

Design

Through a systematic review, untreated and ERT treated males and females with Fabry disease were compared for main clinical outcomes: renal function, left ventricular mass (LVmass), cerebral white matter lesions (WMLs) and end-organ complications. Through a meta-analysis ERT effectiveness was estimated in different disease stages.

Data extraction

Two reviewers assessed quality of the included studies according to guidelines for prognosis research. Data were synthesized using a random effects meta-analysis.

Results

Thirty-one studies were systematically reviewed while six studies were included in the meta-analysis. In patients with a GFR > 60 ml/min/1.73 m², decline of renal function was similar for treated and untreated patients. Only ERT treated males with a GFR < 60 ml/min/1.73 m² had a slower rate of decline in renal function, possibly attributable to anti-proteinuric therapy. Regardless of left ventricular hypertrophy (LVH) at baseline, LVmass remained stable or increased in males despite ERT, however at a slower rate compared to untreated male patients. In ERT treated females with LVH LVmass decreased, and remained stable in females without LVH. WMLs can not be prevented by ERT. Stroke, cardiac and end-stage renal complications develop, though the incidence of new complications seems to be reduced during ERT.

Conclusion

ERT is effective in reducing LVH, but has a limited effect on renal function. Improved treatment options are needed for Fabry disease.

Nur mit Berechtigung zugänglich

Alegra T, Vairo F, de Souza MV, Krug BC, Schwartz IV (2012) Enzyme replacement therapy for Fabry disease: a systematic review and meta-analysis. Genet Mol Biol 35:947–954PubMedCentralPubMedCrossRef

Alfadhel M, Sirrs S (2011) Enzyme replacement therapy for Fabry disease: some answers but more questions. Ther Clin Risk Manag 7:69–82PubMedCentralPubMed

Baehner F, Kampmann C, Whybra C, Miebach E, Wiethoff CM, Beck M (2003) Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Dis 26:617–627PubMedCrossRef

Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86PubMedCrossRef

Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838–844PubMedCrossRef

Beer M, Weidemann F, Breunig F et al (2006) Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy. Am J Cardiol 97:1515–1518PubMedCrossRef

Bierer G, Balfe D, Wilcox WR, Mosenifar Z (2006) Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 29:572–579PubMedCrossRef

Borgwardt L, Feldt-Rasmussen U, Rasmussen A, Ballegaard M, Meldgaard LA (2013) Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet 83:432–438PubMedCrossRef

Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 276:1163–1167PubMedCrossRef

Branton MH, Schiffmann R, Sabnis SG et al (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81:122–138CrossRef

Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69:1216–1221PubMedCrossRef

Buechner S, Moretti M, Burlina AP et al (2008) Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 79:1249–1254PubMedCrossRef

Collin C, Briet M, Tran TC et al (2012) Long-term changes in arterial structure and function and left ventricular geometry after enzyme replacement therapy in patients affected with Fabry disease. Eur J Prev Cardiol 19:43–54PubMedCrossRef

Crutchfield KE, Patronas NJ, Dambrosia JM et al (1998) Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 50:1746–1749PubMedCrossRef

Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43:347–352PubMedCentralPubMedCrossRef

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef

Desnick RJ, Ioannou YA, Eng CM (2001) alpha-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease, vol 3, 8th edn., pp 3733–3774

El Dib RP, Nascimento P, Pastores GM (2013) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2, CD006663PubMed

El Dib RP, Pastores GM (2010) Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev CD006663

Elliott PM, Kindler H, Shah JS et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92:357–360PubMedCentralPubMedCrossRef

Eng CM, Fletcher J, Wilcox WR et al (2007) Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 30:184–192PubMedCrossRef

Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345:9–16PubMedCrossRef

Engelen MA, Brand E, Baumeister TB et al (2012) Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data. BMJ Open 2

Eto Y, Ohashi T, Utsunomiya Y et al (2005) Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 28:575–583PubMedCrossRef

Feriozzi S, Schwarting A, Sunder-Plassmann G, West M, Cybulla M (2009) Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 29:353–361PubMedCrossRef

Feriozzi S, Torras J, Cybulla M, Nicholls K, Sunder-Plassmann G, West M (2012) The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy. Clin J Am Soc Nephrol 7:60–69PubMedCentralPubMedCrossRef

Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547–1557PubMedCrossRef

Grewal RP, Barton NW (1992) Fabry’s disease presenting with stroke. Clin Neurol Neurosurg 94:177–179PubMedCrossRef

Guffon N (2003) Clinical presentation in female patients with Fabry disease. J Med Genet 40:e38PubMedCentralPubMedCrossRef

Gupta S, Ries M, Kotsopoulos S, Schiffmann R (2005) The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore) 84:261–268CrossRef

Hayden JA, Cote P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427–437PubMedCrossRef

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCentralPubMedCrossRef

Hollak CE, Aerts JM, Ayme S, Manuel J (2011) Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders. Orphanet J Rare Dis 6:16PubMedCentralPubMedCrossRef

Hughes DA, Barba Romero MA, Hollak CE, Giugliani R, Deegan PB (2011) Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS-the Fabry Outcome Survey. Mol Genet Metab 103(3):207-14. doi: 10.1016/j.ymgme.2011.03.022

Hughes DA, Elliott PM, Shah J et al (2008) Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 94:153–158PubMedCrossRef

Imbriaco M, Pisani A, Spinelli L et al (2009) Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 95:1103–1107PubMedCrossRef

Jardim L, Vedolin L, Schwartz IV et al (2004) CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 27:229–240PubMedCrossRef

Jardim LB, Aesse F, Vedolin LM et al (2006) White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr 64:711–717PubMedCrossRef

Kalliokoski RJ, Kantola I, Kalliokoski KK et al (2006) The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis 29:112–118PubMedCrossRef

Kampmann C, Linhart A, Baehner F et al (2008a) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367–373PubMedCrossRef

Kampmann C, Linhart A, Devereux RB et al (2009) Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. Clin Ther 31:1966–1976PubMedCrossRef

Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M (2008b) Cardiac manifestations of Anderson-Fabry disease in children and adolescents. Acta Paediatr 97:463–469PubMedCrossRef

Kint JA (1970) Fabry’s disease: alpha-galactosidase deficiency. Science 167:1268–1269PubMedCrossRef

Kobayashi M, OhashiT, Sakuma M, Ida H, EtoY (2008) Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis doi:10.1007/s10545-007-0740-6

Koskenvuo JW, Hartiala JJ, Nuutila P et al (2008) Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis 31:432–441PubMedCrossRef

Kovacevic-Preradovic T, Zuber M, Attenhofer Jost CH et al (2008) Anderson-Fabry disease: long-term echocardiographic follow-up under enzyme replacement therapy. Eur J Echocardiogr 9:729–735PubMedCrossRef

Levey AS, Coresh J, Balk E et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137–147PubMedCrossRef

Lidove O, West ML, Pintos-Morell G et al (2010) Effects of enzyme replacement therapy in Fabry disease–a comprehensive review of the medical literature. Genet Med 12:668–679PubMedCrossRef

Lubanda JC, Anijalg E, Bzduch V, Thurberg BL, Benichou B, Tylki-Szymanska A (2009) Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease. Genet Med 11:256–264PubMedCrossRef

MacDermot KD, Holmes A, Miners AH (2001a) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769–775PubMedCentralPubMedCrossRef

MacDermot KD, Holmes A, Miners AH (2001b) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760PubMedCentralPubMedCrossRef

Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374:1986–1996PubMedCrossRef

Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236–242PubMedCrossRef

Messalli G, Imbriaco M, Avitabile G et al (2012) Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Radiol Med 117:19–28PubMedCrossRef

Mitsias P, Levine SR (1996) Cerebrovascular complications of Fabry’s disease. Ann Neurol 40:8–17PubMedCrossRef

Moore DF, Altarescu G, Herscovitch P, Schiffmann R (2002) Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2:4PubMedCentralPubMedCrossRef

Motwani M, Banypersad S, Woolfson P, Waldek S (2012) Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol Genet Metab 107:197–202PubMedCrossRef

Nakao S, Takenaka T, Maeda M et al (1995) An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 333:288–293PubMedCrossRef

Niemann M, Breunig F, Beer M et al (2010) The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 96:1915–1919PubMedCrossRef

Ortiz A, Cianciaruso B, Cizmarik M et al (2010) End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 25:769–775PubMedCrossRef

Patel MR, Cecchi F, Cizmarik M et al (2011) Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol 57:1093–1099PubMedCrossRef

Pisani A, Spinelli L, Sabbatini M et al (2005) Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis 46:120–127PubMedCrossRef

Pisani A, Spinelli L, Visciano B et al (2013) Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. JIMD Rep 9:41–48PubMedCentralPubMedCrossRef

Ramaswami U, Parini R, Kampmann C, Beck M (2011) Safety of agalsidase alfa in patients with Fabry disease under 7 years. Acta Paediatr 100:605–611PubMedCrossRef

Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M (2012) Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey. Clin Genet 81:485–490PubMedCrossRef

Ramaswami U, Wendt S, Pintos-Morell G et al (2007) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96:122–127PubMedCrossRef

Reisin RC, Romero C, Marchesoni C et al (2011) Brain MRI findings in patients with Fabry disease. J Neurol Sci 305:41–44PubMedCrossRef

Ries M, Clarke JT, Whybra C et al (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118:924–932PubMedCrossRef

Rombach SM, Aerts JM, Poorthuis BJ et al (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 7:e47805PubMedCentralPubMedCrossRef

Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47PubMedCentralPubMedCrossRef

Schiffmann R (2009) Fabry disease. Pharmacol Ther 122:65–77PubMedCrossRef

Schiffmann R, Askari H, Timmons M et al (2007) Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 18:1576–1583PubMedCentralPubMedCrossRef

Schiffmann R, Kopp JB, Austin HA III et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743–2749PubMedCrossRef

Schiffmann R, Martin RA, Reimschisel T et al (2010) Four-year prospective clinical trial of agalsidase alfa in children with Fabry disease. J Pediatr 156(832–7):837

Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21:345–354PubMedCrossRef

Schiffmann R, Warnock DG, Banikazemi M et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24:2102–2111PubMedCentralPubMedCrossRef

Schwarting A, Dehout F, Feriozzi S, Beck M, Mehta A, Sunder-Plassmann G (2006) Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 66:77–84PubMed

Shah JS, Hughes DA, Sachdev B et al (2005a) Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 96:842–846PubMedCrossRef

Shah JS, Lee P, Hughes D et al (2005b) The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart 91:533–534PubMedCentralPubMedCrossRef

Sims K, Politei J, Banikazemi M, Lee P (2009) Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40:788–794PubMedCrossRef

Smid BE, Rombach SM, Aerts JM et al (2011) Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 6:69PubMedCentralPubMedCrossRef

Spinelli L, Pisani A, Sabbatini M et al (2004) Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease. Clin Genet 66:158–165PubMedCrossRef

Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609–2617PubMedCrossRef

Takenaka T, Teraguchi H, Yoshida A et al (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51:50–59PubMedCrossRef

Tondel C, Bostad L, Larsen KK et al (2013) Agalsidase benefits renal histology in young patients with Fabry disease. J Am Soc Nephrol 24:137–148PubMedCrossRef

Tsuboi K, Yamamoto H (2012) Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med 14:779–786PubMedCentralCrossRef

Vedder AC, Linthorst GE, Houge G et al (2007a) Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One 2:e598PubMedCentralPubMedCrossRef

Vedder AC, Linthorst GE, van Breemen MJ et al (2007b) The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 30:68–78PubMedCrossRef

Wanner C, Oliveira JP, Ortiz A et al (2010) Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry registry. Clin J Am Soc Nephrol 5(12):2220-8. doi: 10.2215/CJN.04340510

Warnock DG, Ortiz A, Mauer M et al (2011) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27(3):1042-9. doi: 10.1093/ndt/gfr420

Warnock DG, Ortiz A, Mauer M et al (2012) Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant 27:1042–1049PubMedCentralPubMedCrossRef

Weidemann F, Breunig F, Beer M et al (2003) Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 108:1299–1301PubMedCrossRef

Weidemann F, Niemann M, Breunig F et al (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119:524–529PubMedCrossRef

Weidemann F, Niemann M, Stork S et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274(4):331-41. doi: 10.1111/joim.12077

West M, Nicholls K, Mehta A et al (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20:1132–1139PubMedCentralPubMedCrossRef

Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M (2007) Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int 72:632–637PubMedCrossRef

Whybra C, Miebach E, Mengel E et al (2009) A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 11:441–449PubMedCrossRef

Wilcox WR, Banikazemi M, Guffon N et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75:65–74PubMedCentralPubMedCrossRef

Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112–128PubMedCrossRef

Wraith JE, Tylki-Szymanska A et al (2008) Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr 152(563–70):570

Wuest W, Machann W, Breunig F et al (2011) Right ventricular involvement in patients with Fabry’s disease and the effect of enzyme replacement therapy. Rofo 183:1037–1042PubMedCrossRef

Wyatt K, Henley W, Anderson L et al (2012) The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders. Health Technol Assess 16:1–543PubMed

Titel: Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis
Effectiveness of ERT in different disease stages
verfasst von: Saskia M. Rombach
Bouwien E. Smid
Gabor E. Linthorst
Marcel G. W. Dijkgraaf
Carla E. M. Hollak
Publikationsdatum: 01.05.2014
Verlag: Springer Netherlands
Erschienen in: Journal of Inherited Metabolic Disease / Ausgabe 3/2014
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-014-9677-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis

Effectiveness of ERT in different disease stages

Abstract

Objective

Design

Data extraction

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objective

Design

Data extraction

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Abetalipoproteinemia and homozygous hypobetalipoproteinemia: a framework for diagnosis and management

Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS)

A suspicion index for early diagnosis and treatment of cerebrotendinous xanthomatosis

Update on transcobalamin deficiency: clinical presentation, treatment and outcome

Valproyl-CoA inhibits the activity of ATP- and GTP-dependent succinate:CoA ligases

Metabolic biology of 3-methylglutaconic acid-uria: a new perspective

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Update Innere Medizin